Develops bispecific therapeutic antibodies that engage immune cells to target and eliminate solid tumors, particularly those resistant to immune checkpoint inhibitors. By optimizing the potencies of immune-engaging arms and improving tumor localization, these antibodies aim to provide effective treatment with reduced side effects, addressing critical gaps in cancer immunotherapy.
Funding
$67M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CPRTFounders
Product
Problem
Many solid tumors are resistant to existing immune checkpoint inhibitors, leaving a significant unmet need for effective cancer immunotherapies. Traditional bispecific antibody designs optimized for blood cancers often fail to translate effectively to solid tumors due to dose-limiting toxicities and poor tumor localization.
Solution
Rondo Therapeutics develops next-generation, immune-cell engaging bispecific antibodies engineered to target and eliminate solid tumors. Their antibodies are designed to maximize efficacy while minimizing side effects by tuning the potencies of immune-engaging arms and improving tumor localization. This approach aims to provide clinicians with flexible dosing strategies and combination regimens to deliver optimal results for patients with solid tumors. The company utilizes NGS-based antibody discovery to rapidly develop diverse binding arm collections and employs proprietary functional and developability screens to identify clinically viable molecules.
Target Audience
The primary target audience includes clinicians treating solid tumors, as well as pharmaceutical companies seeking strategic partnerships for synergistic advancement of clinical assets.
Features
- Bispecific antibodies designed to engage immune cells and target solid tumors
- Optimized therapeutic window to maximize efficacy and minimize dose-limiting toxicities
- Tuned potencies of immune-engaging arms for improved safety and efficacy
- Enhanced tumor localization to concentrate immune activity at the tumor site
- Fixed-light chain format allows for flexible pairing of immune effector and tumor-targeting arms
- NGS-based antibody discovery for rapid development of diverse binding arm collections
- Proprietary functional and developability screens to identify clinically viable molecules
- Multi-product pipeline targeting a range of solid tumor indications, including bladder and ovarian cancer